走进邦泰

The latest research from the Chinese Academy of Sciences: NAD+ and NMN can treat COVID-19

Source:bontac

Release Time: 2022-05-12 09:05:46

26 Views

分享到:

The COVID-19 epidemic has spread rapidly and caused the death of over 6 million people. As we all know, patients with critical COVID-19 develop severe respiratory distress, and many die from it. Although vaccines with efficiency and protection have been developed, the Rapid mutation ability of SARS-CoV-2 has brought massive uncertainty to the COVID-19 epidemic, prioritizing the development of drugs for COVID-19 treatment.

April 29, 2022, the Chinese Academy of Sciences and the Beijing Institute of Microbiology and Epidemiology and Tsingsenghua jointly published a research article on Cell Discovery  named  “Treatment of SARS-CoV-2-induced pneumonia with NAD+ and NMN in two mouse models”.

In this research, researchers found that COVID-19 infection leads to the dysregulation of genes of the mouse, which related to the NAD+ metabolism, immune response and cell death, similar to that in COVID-19 patients.

The importance and benefits of NAD+ and NADH for humans has proven in many papers. They are essential coenzymes for a variety of cellular energy metabolism pathways, such as the TCA cycle and oxidative phosphorylation; they govern the body's metabolism and the generation of direct energy sources, respectively. In the meantime, they also participate in many critical biological processes, including cell survival, aging, inflammation, etc. Its significance to human beings needs no further elaboration. This is why Bontac insisted on researching and developing effective NAD and intermediate NMN products from the company’s establishment.

Last year, Pang et al. found that NAD+ supplementation was effective in attenuating cell death and inhibiting microglial activation in the brains of Zika virus (ZIKV)-infected mice. Therefore, the researchers studied the therapeutic effect of NAD+ and its intermediate NMN on COVID-19 on the basis of this discovery.

First, through treatment, researchers found that the pneumonia phenotypes, including excessive inflammatory cell infiltration, hemolysis, and embolization in SARS-CoV-2-infected lungs were significantly rescued. (Fig.1)

NAD+ and NMN can treat COVID-19

                                                                                                                               Fig. 1

Second, researchers found that cell death was suppressed substantially by NAD+ and NMN supplementation (Fig. 2). More strikingly, NMN supplementation can protect 30% of aged mice infected with the lethal mouse-adapted SARS-CoV-2 from death (Fig. 3).

Fig. 2

Finally, researchers found that NAD+ or NMN supplementation partially rescued the disturbed gene expression and metabolism caused by COVID-19 infection(Fig. 4, Fig. 5).

Fig. 4

In conclusion, this research in vivo mouse supports trials for treating COVID-19 patients by targeting the NAD+ pathway. Trials should consider NAD+ and its intermediate NMN to treat patients with COVID-19.

 

Reference:

Jiang, Y., Deng, Y., Pang, H. et al. Treatment of SARS-CoV-2-induced pneumonia with NAD+ and NMN in two mouse models. Cell Discov 8, 38 (2022).